

Gernot Riedel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3532517/publications.pdf>

Version: 2024-02-01

58
papers

2,250
citations

257357

24
h-index

233338

45
g-index

60
all docs

60
docs citations

60
times ranked

3512
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarin (CBDV), Δ^9 -tetrahydrocannabinol (THC) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. <i>Psychopharmacology</i> , 2012, 219, 859-873.	1.5	295
2	Potential of Low Dose Leuco-Methylthionium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 435-457.	1.2	142
3	Parvalbumin-positive interneurons of the prefrontal cortex support working memory and cognitive flexibility. <i>Scientific Reports</i> , 2015, 5, 16778.	1.6	134
4	Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. <i>British Journal of Pharmacology</i> , 2009, 156, 1154-1166.	2.7	120
5	Abnormal Cognition, Sleep, EEG and Brain Metabolism in a Novel Knock-In Alzheimer Mouse, PLB1. <i>PLoS ONE</i> , 2011, 6, e27068.	1.1	115
6	Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. <i>Neuropharmacology</i> , 2004, 47, 1170-1179.	2.0	98
7	EEG, Activity, and Sleep Architecture in a Transgenic Δ^2 PPswe/PSEN1A246E Alzheimer's Disease Mouse. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 873-887.	1.2	92
8	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. <i>Neurobiology of Disease</i> , 2016, 91, 59-68.	2.1	78
9	Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology. <i>Neurobiology of Disease</i> , 2016, 91, 105-123.	2.1	68
10	Memantine Acts as a Cholinergic Stimulant in the Mouse Hippocampus. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 319-333.	1.2	64
11	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. <i>Experimental Neurology</i> , 2015, 273, 36-44.	2.0	58
12	Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease. <i>Glia</i> , 2016, 64, 386-395.	2.5	56
13	Knock-In of Human BACE1 Cleaves Murine APP and Reiterates Alzheimer-like Phenotypes. <i>Journal of Neuroscience</i> , 2014, 34, 10710-10728.	1.7	52
14	Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. <i>Psychopharmacology</i> , 2008, 198, 551-563.	1.5	50
15	Neuronal human BACE1 knockin induces systemic diabetes in mice. <i>Diabetologia</i> , 2016, 59, 1513-1523.	2.9	50
16	Comparison of automated home-cage monitoring systems: Emphasis on feeding behaviour, activity and spatial learning following pharmacological interventions. <i>Journal of Neuroscience Methods</i> , 2014, 234, 13-25.	1.3	48
17	Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat. <i>Learning and Memory</i> , 2010, 17, 502-511.	0.5	47
18	WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. <i>Behavioural Brain Research</i> , 2010, 208, 584-592.	1.2	46

#	ARTICLE	IF	CITATIONS
19	Measuring Behavior in the Home Cage: Study Design, Applications, Challenges, and Perspectives. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 735387.	1.0	46
20	Between and within laboratory reliability of mouse behaviour recorded in home-cage and open-field. <i>Journal of Neuroscience Methods</i> , 2018, 300, 10-19.	1.3	45
21	Introduction to the EQIPD quality system. <i>ELife</i> , 2021, 10, .	2.8	42
22	Altered Cellular Distribution of Phospho-Tau Proteins Coincides with Impaired Retrograde Axonal Transport in Neurons of Aged Rats. <i>Annals of the New York Academy of Sciences</i> , 2005, 1048, 287-295.	1.8	37
23	Progressive age-related changes in sleep and EEG profiles in the PLB1Triple mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2768-2784.	1.5	32
24	FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2011, 39, 874-880.	1.6	29
25	A Protein Aggregation Inhibitor, Leuco-Methylthionium Bis(Hydromethanesulfonate), Decreases β -Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 447.	1.4	28
26	Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 755-778.	1.2	27
27	Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 931-946.	1.2	26
28	Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. <i>Behavioural Pharmacology</i> , 2015, 26, 289-303.	0.8	21
29	Alpha-Synuclein transgenic mice, h β -SynL62, display β -Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease. <i>Behavioural Brain Research</i> , 2018, 339, 153-168.	1.2	21
30	Cytoskeletal Transport in the Aging Brain: Focus on the Cholinergic System. <i>Reviews in the Neurosciences</i> , 2006, 17, 581-618.	1.4	19
31	Recruitment of hippocampal neurons to encode behavioral events in the rat: Alterations in cognitive demand and cannabinoid exposure. <i>Hippocampus</i> , 2010, 20, 1083-1094.	0.9	19
32	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. <i>Current Alzheimer Research</i> , 2020, 17, 285-296.	0.7	18
33	No spatial working memory deficit in β -amyloid-exposed rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 955-970.	2.5	17
34	A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats. <i>Sleep Disorders</i> , 2011, 2011, 1-7.	0.8	17
35	Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 501-519.	1.2	17
36	Sleep and hippocampus: Do we search for the right things?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 806-812.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Long-term study of chronic oral aluminum exposure and spatial working memory in rats.. Behavioral Neuroscience, 2002, 116, 351-356.	0.6	14
38	Functional effects of polymorphisms on glucocorticoid receptor modulation of human anxiogenic substance-P gene promoter activity in primary amygdala neurones. Psychoneuroendocrinology, 2014, 47, 43-55.	1.3	13
39	The interoceptive hippocampus: Mouse brain endocrine receptor expression highlights a dentate gyrus (DG)â€“cornu ammonis (CA) challengeâ€“sufficiency axis. PLoS ONE, 2020, 15, e0227575.	1.1	13
40	Cannabinoids and their therapeutic applications in mental disorders. Dialogues in Clinical Neuroscience, 2020, 22, 271-279.	1.8	13
41	Detection of time-, frequency- and direction-resolved communication within brain networks. Scientific Reports, 2018, 8, 1825.	1.6	12
42	Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimerâ€™s disease and frontotemporal lobar degeneration. Brain Communications, 2020, 2, fcaa033.	1.5	12
43	Increased Cholinergic Response in $\hat{\pm}$ -Synuclein Transgenic Mice (h- $\hat{\pm}$ -synL62). ACS Chemical Neuroscience, 2019, 10, 1915-1922.	1.7	11
44	Of mice and motion: Behavioural-EEG phenotyping of Alzheimerâ€™s disease mouse models. Journal of Neuroscience Methods, 2019, 319, 89-98.	1.3	9
45	Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia. Journal of Biological Chemistry, 2020, 295, 18508-18523.	1.6	9
46	Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits. Cellular and Molecular Life Sciences, 2015, 72, 4613-4632.	2.4	8
47	Spatial learning and flexibility in 129S2/SvHsd and C57BL/6J mouse strains using different variants of the Barnes maze. Behavioural Pharmacology, 2018, 29, 688-700.	0.8	8
48	The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166149.	1.8	8
49	Cerebellar molecular layer interneurons are dispensable for cued and contextual fear conditioning. Scientific Reports, 2020, 10, 20000.	1.6	7
50	PEERS â€” An Open Science â€œPlatform for the Exchange of Experimental Research Standardsâ€“in Biomedicine. Frontiers in Behavioral Neuroscience, 2021, 15, 755812.	1.0	7
51	Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse. Journal of Alzheimer's Disease, 2018, 65, 165-180.	1.2	4
52	Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine. Journal of Neurochemistry, 2021, , .	2.1	3
53	Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride. Journal of Neuroscience Methods, 2019, 319, 47-59.	1.3	2
54	Introduction: Hippocampal function in spatial memory. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 751-752.	2.5	1

#	ARTICLE	IF	CITATIONS
55	Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks. <i>Cells</i> , 2021, 10, 2162.	1.8	1
56	O3-12-03: GENETICALLY COMPARABLE ALZHEIMER MICE WITH SINGLE (PLB2TAU) OR MULTIPLE (PLB1TRIPLE) RISK GENES HAVE DIFFERENTIAL COGNITIVE AND PATHOLOGICAL PHENOTYPES. , 2014, 10, P233-P233.		0
57	Neuroprotection of cholinergic neurons with tau aggregation inhibitor and rivastigmine in L1 mice with Alzheimer's-like tauopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e042986.	0.4	0
58	HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine. <i>Biomedicines</i> , 2022, 10, 867.	1.4	0